Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of AG0301-COVID19 in Healthy Adults
NCT04463472Phase 2Completed
- Sponsor
- AnGes, Inc.
- Start
- Jun 2020
- Primary completion
- Sep 2020
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of AG0301-COVID19 in coronavirus disease 2019 (COVID-19), sponsored by AnGes, Inc.. Started Jun 2020; status: completed.
02
Drugs
AG0301-COVID19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04463472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04463472.